14:18 , Dec 22, 2016 |  BC Innovations  |  Targets & Mechanisms

Opportunity Knocks

Despite its continued emphasis on tapping external innovation for new opportunities, industry is still leaving on the table scores of unexploited drug targets identified at universities, according to an analysis of BioCentury’s BCIQ: BioCentury Online...
14:17 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD) Cell culture and mouse studies suggest PROK2 could help treat PD. In a rat dopaminergic neural cell line pretreated with the neurotoxicant 1-methyl-4-phenylpyridinium (MPP) to induce PD-like pathology, PROK2 decreased caspase-3 (CASP3;...
07:00 , Oct 20, 2016 |  BC Innovations  |  Product R&D

Chaperoning the DJ

  In the latest example of post-dopamine thinking in Parkinson’s disease, Cantabio Pharmaceuticals Inc. has moved upstream of the neurotransmitter with a strategy to block the protein misfolding and oxidative damage that drive neurodegeneration in the...
07:00 , Sep 29, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Caspase-3 (CASP3; CPP32); cyclin dependent kinase (CDK)

Infectious disease INDICATION: Viral infection Cell culture studies suggest the pan-caspase inhibitor emricasan, the generic antihelminthic niclosamide or CDK inhibitors could help treat Zika. In a Zika virus-infected human glioblastoma cell line, screening of 6,000 approved drugs,...
07:00 , May 12, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Drug-loaded nanoparticles carrying a caspase-3 (CASP3; CPP32)-activated near-infrared (NIR) fluorescent reporter for early imaging of tumor response

Imaging TECHNOLOGY: Fluorescence Polymer nanoparticles loaded with a CASP3-activated NIR fluorescent reporter and anticancer agents could monitor tumor responses to the therapy. The nanoparticles were composed of poly[iso-butylene-alt-(maleic anhydride)] (PIMA) and loaded with a cancer drug plus...
07:00 , May 5, 2016 |  BC Innovations  |  Targets & Mechanisms

Better call Delilah

Long non-coding RNAs (lncRNAs), once confined to the pile of non-functional genomic "junk," are now recognized to play key roles in gene regulation, and are increasingly being explored in various cancers. A Belgian group has...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Clinical News

Emricasan: Phase II data

A double-blind, U.S. Phase II trial in 86 patients with liver cirrhosis showed that twice-daily 25 mg oral emricasan significantly reduced cleaved CK18 levels from baseline to 3 months vs. placebo (reduction of 4.6% vs....
07:00 , May 14, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Procaspase-3; caspase-3 (CASP3; CPP32)

Cancer INDICATION: Cancer In vitro and mouse studies suggest metabolically stable analogs of procaspase-activating compound 1 (PAC-1) could help treat cancer. PAC-1 converts procaspase-3 to CASP3 to induce cell death, but its rapid degradation via multiple oxidation...
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

Emricasan: Additional Phase II data

Additional data from a double-blind, U.S. Phase II trial in 38 patients with NAFLD, including patients with non-alcoholic steatohepatitis (NASH), showed that twice-daily 25 mg emricasan led to a median absolute reduction in ALT levels...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

Emricasan: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 38 patients with NAFLD, including patients with non-alcoholic steatohepatitis (NASH), showed that twice-daily 25 mg emricasan met the primary endpoint of reducing ALT levels from...